Breaking News

Northwest Bio Seeks GMP Certification of Sawston Mfg. Facility

Upon initial license, production of GMP DCVax-L products in the Sawston facility may begin by the end of Q3.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, applied for certification of the manufacturing facility in Sawston, UK with the Medicines and Healthcare Products Regulatory Agency (MHRA). The company also provided a process update on the DCVax-L Phase III Trial.   On May 7, the application package was submitted to the MHRA requesting the certification of the Sawston facility to produce GMP clinical grade medical product...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters